Chemours Enhances EVOLVE 2030 Portfolio Sustainability Assessment Methodology

Chemours’ enhanced methodology now includes product and packaging circularity within its sustainability impact assessment

The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company, today announced the release of EVOLVE 2030 Version 2.0, the Company’s portfolio sustainability assessment methodology. EVOLVE 2030 helps Chemours evaluate its product offerings and product development pipeline in relation to the United Nations Sustainable Development Goals (UN SDGs). The evaluation criteria assist Chemours in demonstrating progress against its 2030 Corporate Responsibility Commitment goal to generate 50% or more of its revenue from offerings that make a specific contribution to the UN SDGs. The updated methodology now includes considerations on product and packaging circularity, as well as insights gained from Chemours’ experience using the methodology over the last four years.

Chemours’ EVOLVE 2030 methodology uses sustainability information and insights to inform decisions on its product portfolio, investments in innovations, and resource allocation. This data-driven, science-based, and holistic methodology is designed to maximize the positive impact of Chemours’ products on society while minimizing their planetary burdens.

"Chemours is driven by our strong commitment to sustainability. The updated EVOLVE 2030 methodology enhances our ability to align our business processes with this commitment, allowing us to better quantify the societal and environmental impacts of our products and guide our decisions accordingly," said Dr. Amber Wellman, Chief Sustainability Officer at Chemours. "By incorporating lessons learned and maintaining our approach of continuous improvement, we are enabling a future where our products not only meet market needs but also contribute positively to our shared planet.”

Established in 2019, EVOLVE 2030 is grounded in the World Business Council for Sustainable Development’s (WBCSD) Chemical Industry Methodology for Portfolio Sustainability Assessments (PSA). Chemours evaluates its offerings based on a Product—Application Combination (PAC) approach, which considers a product’s benefits and burdens throughout its life cycle, including its contribution to the UN SDGs and its overall impact – or "Imprint" – on people and the planet. By examining its products' contributions to the UN SDGs and their overall impact on society and the environment, Chemours is strengthening its resolve to steer its product portfolio to support a more sustainable future.

EVOLVE 2030 was developed in partnership with Anthesis Group, a global sustainability advisor, and received third-party assurance from Lloyd’s Register Quality Assurance in 2019 and 2024. Click here to read Chemours’ EVOLVE 2030 methodology.

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our flagship products are sold under prominent brands such as Ti-Pure™, Opteon™, Freon™, Teflon™, Viton™, Nafion™, and Krytox™. The Company has approximately 6,200 employees and 28 manufacturing sites, and serves approximately 2,700 customers in approximately 110 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

For more information, we invite you to visit chemours.com or follow us on X (formerly Twitter) @Chemours or on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, our 2030 Corporate Responsibility Commitment goals and progress towards those goals, and our expectation of meeting market needs and making positive environmental contributions, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604161046/en/